

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
2099.0010001/JAG/LAVAPPLICATION NO.  
10/690,639FIRST NAMED INVENTOR  
Silanes *et al.*FILING DATE  
October 23, 2003ART UNIT  
1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
UK	AA1	4,806,346	02/21/1989	Hum <i>et al.</i>			12/16/1986
	AB1	4,814,433	03/21/1989	Fredrickson			09/16/1987
	AC1	4,849,352	07/18/1989	Sullivan <i>et al.</i>			10/09/1984
	AD1	4,940,670	07/10/1990	Rhodes			04/09/1986
	AE1	5,328,834	07/12/1994	Ngo <i>et al.</i>			09/08/1989
	AF1	5,733,742	03/31/1998	Landon			03/10/1995
	AG1	5,888,511	03/30/1999	Skurkovich <i>et al.</i>			12/23/1996
	AH1	6,333,032	12/25/2001	Skurkovich <i>et al.</i>			12/22/1997
	AI1	6,534,059	03/18/2003	Skurkovich <i>et al.</i>			01/28/2001
	AJ1	6,709,655	03/23/2004	López de Silanes <i>et al.</i>			03/05/2001
UK	AK1	2003/0215448	11/20/2003	Skurkovich <i>et al.</i>			03/14/2003

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
UK	AL1	2 106 183	11/01/1997	Spain			Yes No X
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

UK	AR	1	Cain, B.S., <i>et al.</i> , "The Physiologic Basis for Anticytokine Clinical Trials in the Treatment of Sepsis," <i>J. Am. Coll. Surg.</i> 186:337-351, American College of Surgeons (1998)
UK	AS	1	Fekade, D., <i>et al.</i> , "Prevention of Jarisch-Herxheimer Reactions by Treatment with Antibodies Against Tumor Necrosis Factor $\alpha$ ," <i>N. Engl. J. Med.</i> 335:311-315, Massachusetts Medical Society (1996)
UK	AT	1	Fox, D.A., "Cytokine Blockade as a New Strategy to Treat Rheumatoid Arthritis," <i>Arch. Intern. Med.</i> 160:437-444, American Medical Association (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
2099.0010001/JAG/LAVAPPLICATION NO.  
10/690,639FIRST NAMED INVENTOR  
Silanes *et al.*FILING DATE  
October 23, 2003ART UNIT  
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
UK	AA2	2003/0223995	12/04/2003	Skurkovich <i>et al.</i>	X	X	11/26/2002
	AB2	2003/0224005	12/04/2003	Skurkovich <i>et al.</i>			02/21/2003
	AC2	2003/0228310	12/11/2003	Skurkovich <i>et al.</i>			11/26/2002
	AD2	2004/0062768	04/01/2004	Skurkovich <i>et al.</i>			08/05/2003
UK	AE2	2004/0086508	05/06/2004	Skurkovich <i>et al.</i>			07/30/2003
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

UK	AR	2	Krueger, J.G., "The immunologic basis for the treatment of psoriasis with new biologic agents," <i>J. Am. Acad. Dermatol.</i> 46:1-23, Mosby (2002)
UK	AS	2	Lisman, K.A., <i>et al.</i> , "Managing Heart Failure with Immunomodulatory Agents," <i>Cardiol. Clin.</i> 19:617-625, W.B. Saunders Co. (2001)
UK	AT	2	Luger, T., "Treatment of immune-mediated skin disease: future perspectives," <i>Eur. J. Dermatol.</i> 11:343-347, John Libbey Eurotext (2003), downloaded from: < <a href="http://www.john-libbey-eurotext.fr/en/revues/medecine/ejd/e-docs/00/01/88/A6/article.md">http://www.john-libbey-eurotext.fr/en/revues/medecine/ejd/e-docs/00/01/88/A6/article.md</a> >

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
2099.0010001/JAG/LAVAPPLICATION NO.  
10/690,639FIRST NAMED INVENTOR  
Silanes *et al.*FILING DATE  
October 23, 2003ART UNIT  
1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

UPK	AR	3	Martin, G.S., "Current Management Strategies for Severe Sepsis and Septic Shock," Presented at Chest 2001: 67th Annual Scientific Assembly of the American College of Chest Physicians, November 4 - 8, 2001, Philadelphia, PA, downloaded from: <a href="http://www.medscape.com/viewarticle/412927">http://www.medscape.com/viewarticle/412927</a>
UPK	AS	3	Present, D.H., <i>et al.</i> , "Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease," <i>N. Engl. J. Med.</i> 340:1398-1405, Massachusetts Medical Society (1999)
UPK	AT	3	Qian, Y., <i>et al.</i> , "Topical Soluble Tumor Necrosis Factor Receptor Type I Suppresses Ocular Chemokine Gene Expression and Rejection of Allogenic Corneal Transplants," <i>Arch. Ophthalmol.</i> 118:1666-1671, American Medical Association (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
2099.0010001/JAG/LAVAPPLICATION NO.  
10/690,639FIRST NAMED INVENTOR  
Silanes *et al.*FILING DATE  
October 23, 2003ART UNIT  
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

CHK	AR	4	Stapczynski, J.S., "Shock, Septic," Dire, D.J., <i>et al.</i> , eds., eMedicine.com Inc., (2004), downloaded from: < <a href="http://emedicine.com/EMERG/topic533.htm">http://emedicine.com/EMERG/topic533.htm</a> >
CHK	AS	4	Torres, P.F., and Kijlstra, A., "The role of cytokines in corneal immunopathology," <i>Ocul. Immunol. Inflamm.</i> 9:9-24, Swets & Zeitlinger (2001)
CHK	AT	4	Zhu, S., <i>et al.</i> , "Early Expression of Proinflammatory Cytokines Interleukin-1 and Tumor Necrosis Factor- $\alpha$ after Corneal Transplantation," <i>J. Interferon. Cytokine. Res.</i> 19:661-669, Mary Ann Liebert, Inc. (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
2099.0010001/JAG/LAVAPPLICATION NO.  
10/690,639FIRST NAMED INVENTOR  
Silanes *et al.*FILING DATE  
October 23, 2003ART UNIT  
1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OK	AR	5	Abstract of Dick, A.D., <i>et al.</i> , "Neutralizing TNF- $\alpha$ Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis," <i>J. Autoimmun.</i> 11:255-264, Academic Press (1998), downloaded from: < <a href="http://80-www.elsevier.com.proxygw.wrlc.org/wps/find/journaldescription.cws_home/622856/description">http://80-www.elsevier.com.proxygw.wrlc.org/wps/find/journaldescription.cws_home/622856/description</a> >
UHC	AS	5	<del>International Search Report for International Patent Application No. PCT/MX02/0013, mailed August 16, 2002</del>
	AT	5	Dialog File 351, Accession No. 9271133, Derwent WPI English language abstract for Spanish Patent No. 2 106 183 (Document AL1)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

**INFORMATION DISCLOSURE STATEMENT**ATTY. DOCKET NO.  
2099.0010001/JAG/LAVAPPLICATION NO.  
10/690,639FIRST NAMED INVENTOR  
Silanes *et al.*FILING DATE  
October 23, 2003ART UNIT  
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

UK	AR	6	English language translation of Secretaría de Salud, "Potency of Anti-Poison Sera," in <i>Farmacopea de los Estados Unidos Mexicanos</i> , Vol. II, Secretaría de Salud, Mexico City, MX, pp. 1756-1757 (2000)
UK	AS	6	English language translation of Secretaría de Salud, "Pyrogen Tests," in: <i>Farmacopea de los Estados Unidos Mexicanos</i> , Vol. I, Secretaría de Salud, Mexico City, MX, pp. 334-335 (2000)
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449		Page 1 of 2					
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 2099.0010001/JAG/LAV					
		APPLICATION NO. 10/690,639					
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		FIRST NAMED INVENTOR Silanes <i>et al.</i>					
		FILING DATE October 23, 2003					
<b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		ART UNIT 1644					
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
<i>DK</i>	AF2	6,448,054 B1	09/10/2002	Poznansky <i>et al.</i>			04/07/2000
<i>CK</i>	AG2	2003/0049725 A1	03/13/2003	Heavner <i>et al.</i>			08/01/2001
	AH						
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
<i>DK</i>	AM1	WO 92/22324	12/23/1992	WIPO			Yes No
<i>CK</i>	AN1	WO 01/58469	08/16/2001	WIPO			Yes No
	AO						Yes No
	AP						Yes No
<b>OTHER (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AR						
	AS						
<i>CK</i>	AT	6	Calderon-Aranda, E.S., <i>et al.</i> , "Neutralizing capacity of murine sera induced by different antigens of scorpion venom," <i>Toxicon</i> 31:327-337, Pergamon Press Ltd. (1993)				
EXAMINER					DATE CONSIDERED		
<i>[Signature]</i>					3/7/06		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENTATTY. DOCKET NO.  
2099.0010001/JAG/LAVAPPLICATION NO.  
10/690,639FIRST NAMED INVENTOR  
Silanes *et al.*FILING DATE  
October 23, 2003ART UNIT  
1644


## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	Z	Licea, A.F., <i>et al.</i> , FAB fragments of the monoclonal antibody BCF2 are capable of neutralizing the whole venom from the scorpion <i>Centruroides noxius hoffman</i> , "Toxicon 34:843-847, Pergamon Press Ltd. (1996)
	AS	Z	
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.